PRMT5-MTA Inhibitor Selectivity in MTAP-Deleted Tumor Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRMT5 inhibitors exhibit strong blood toxicity due to their potent inhibitory activity against both normal cells and tumor cells, limiting their clinical applications and impacting therapy outcomes.
Innovation Solution
Development of specific compounds that inhibit PRMT5 activity in tumor cells by leveraging MTAP deletion, which leads to intracellular accumulation of MTA, thereby enhancing selective inhibition in tumor cells with minimal effect on normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 inhibitors are used to inhibit PRMT5 activity in both normal cells and tumor cells, then anti-tumor efficacy is improved, but blood toxicity increases
Solution Approach 1:
The patent applies local quality by designing inhibitors with selective affinity for PRMT5 in MTAP-deficient tumor cells versus normal cells. The compounds exploit the unique biochemical environment (MTA accumulation) in specific tumor cells to achieve localized inhibition, thereby maintaining anti-tumor efficacy while reducing systemic toxicity to normal cells and blood components.
Solution Approach 2:
The patent utilizes parameter changes by leveraging the differential intracellular MTA concentration between MTAP-deficient tumor cells and normal cells. The inhibitors are designed to respond to this parameter difference, with their inhibitory activity modulated by MTA levels, thus achieving selective toxicity based on the biochemical parameter variation across different cell types.
2Reliability
If PRMT5 inhibitors are designed to be potent against PRMT5, then inhibitory activity is improved, but selectivity between tumor cells and normal cells decreases
Solution Approach 1:
The patent introduces MTA as an intermediary that mediates the selectivity mechanism. The inhibitors do not directly target PRMT5 with uniform potency across all cells; instead, their effective inhibition is mediated through the presence of accumulated MTA in MTAP-deficient tumor cells. This intermediary creates a bridge between the inhibitor and PRMT5, enabling potent inhibition only in the appropriate cellular context.
Solution Approach 2:
The inhibitors exhibit local quality in their inhibitory action, with high potency localized to MTAP-deficient tumor cells where MTA accumulates, while showing reduced activity in normal cells with functional MTAP. This spatial and cellular specificity allows the compounds to maintain high inhibitory activity where needed while preserving normal cell function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide a therapeutic safety window with potent anti-tumor efficacy while reducing toxicity in normal cells by exploiting MTAP-deficient tumor cells' unique biochemical properties.
Implementation Method 1
MTAP deletion can lead to intracellular accumulation of MTA
Implementation Method 2
MTA competes for binding to PRMT5 with the methyl donor SAM of its functional substrate, thereby inhibiting the function of PRMT5
Data Source
AI summary
Provided in the present invention is a compound as a PRMT5-MTA inhibitor, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Further provided in the present invention are a pharmaceutical composition containing the compound and the use thereof in the treatment of cancers.